Steminent Biotherapeutics Inc.
Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It offers Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington's disease; tissue regeneration, such as osteoarthritis; and acute syndromes comprising acute respiratory distress syndrome, liver failure, and ischemic s… Read more
Steminent Biotherapeutics Inc. (7729) - Total Liabilities
Latest total liabilities as of June 2025: NT$97.53 Million TWD
Based on the latest financial reports, Steminent Biotherapeutics Inc. (7729) has total liabilities worth NT$97.53 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Steminent Biotherapeutics Inc. - Total Liabilities Trend (2020–2024)
This chart illustrates how Steminent Biotherapeutics Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Steminent Biotherapeutics Inc. Competitors by Total Liabilities
The table below lists competitors of Steminent Biotherapeutics Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Scherzer & Co. AG
F:PZS
|
Germany | €8.01 Million |
|
Prospect Capital Corporation
NASDAQ:PSEC
|
USA | $2.01 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Steminent Biotherapeutics Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Steminent Biotherapeutics Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Steminent Biotherapeutics Inc. (2020–2024)
The table below shows the annual total liabilities of Steminent Biotherapeutics Inc. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$81.97 Million | -18.76% |
| 2023-12-31 | NT$100.89 Million | +39.91% |
| 2022-12-31 | NT$72.11 Million | +104.69% |
| 2021-12-31 | NT$35.23 Million | -68.87% |
| 2020-12-31 | NT$113.17 Million | -- |